Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.52 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538446 | 0.92 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL18538450 | 0.87 | HDAC8 (0.63) | HDAC8LY96 | |
| SCHEMBL18538455 | 0.84 | HDAC8 (0.60) | HDAC8LY96 | |
| SCHEMBL21064515 | 0.82 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL21064511 | 0.81 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL21507723 | 0.81 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL21064510 | 0.80 | HDAC8 (0.98) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL21064506 | 0.79 | HDAC8 (0.77) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL16516744 | 0.79 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL18542270 | 0.77 | LY96 (0.74) | HDAC8HDAC3HDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885HDAC3 9/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.